- Home
- REFI vs DRTS Comparison
REFI vs DRTS Comparison
Compare REFI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- DRTS
- Stock Information
- Founded
- REFI 2021
- DRTS 2015
- Country
- REFI United States
- DRTS Israel
- Employees
- REFI N/A
- DRTS N/A
- Industry
- REFI Real Estate Investment Trusts
- DRTS Medical/Dental Instruments
- Sector
- REFI Real Estate
- DRTS Health Care
- Exchange
- REFI Nasdaq
- DRTS Nasdaq
- Market Cap
- REFI 255.6M
- DRTS 300.2M
- IPO Year
- REFI 2021
- DRTS N/A
- Fundamental
- Price
- REFI $12.91
- DRTS $3.87
- Analyst Decision
- REFI Strong Buy
- DRTS Strong Buy
- Analyst Count
- REFI 3
- DRTS 1
- Target Price
- REFI $20.00
- DRTS $9.00
- AVG Volume (30 Days)
- REFI 130.6K
- DRTS 67.8K
- Earning Date
- REFI 11-04-2025
- DRTS 11-18-2025
- Dividend Yield
- REFI 15.96%
- DRTS N/A
- EPS Growth
- REFI N/A
- DRTS N/A
- EPS
- REFI 1.69
- DRTS N/A
- Revenue
- REFI $54,287,847.00
- DRTS N/A
- Revenue This Year
- REFI $11.43
- DRTS N/A
- Revenue Next Year
- REFI $4.75
- DRTS N/A
- P/E Ratio
- REFI $7.62
- DRTS N/A
- Revenue Growth
- REFI N/A
- DRTS N/A
- 52 Week Low
- REFI $12.00
- DRTS $2.14
- 52 Week High
- REFI $16.29
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- REFI 46.72
- DRTS 45.26
- Support Level
- REFI $12.71
- DRTS $3.80
- Resistance Level
- REFI $13.24
- DRTS $4.21
- Average True Range (ATR)
- REFI 0.23
- DRTS 0.26
- MACD
- REFI 0.03
- DRTS -0.03
- Stochastic Oscillator
- REFI 53.13
- DRTS 17.11
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.